The lipoprotein-associated coagulation inhibitor that inhibits the factor VII-tissue factor complex also inhibits factor Xa: insight into its possible mechanism of action
- PMID:3422166
The lipoprotein-associated coagulation inhibitor that inhibits the factor VII-tissue factor complex also inhibits factor Xa: insight into its possible mechanism of action
Abstract
Blood coagulation is initiated when plasma factor VII(a) binds to its essential cofactor tissue factor (TF) and proteolytically activates factors X and IX. Progressive inhibition of TF activity occurs upon its addition to plasma. This process is reversible and requires the presence of VII(a), catalytically active Xa, Ca2+, and another component that appears to be associated with the lipoproteins in plasma, a lipoprotein-associated coagulation inhibitor (LACI). A protein, LACI(HG2), possessing the same inhibitory properties as LACI, has recently been isolated from the conditioned media of cultured human liver cells (HepG2). Rabbit antisera raised against a synthetic peptide based on the N-terminal sequence of LACI(HG2) and purified IgG from a rabbit immunized with intact LACI(HG2) inhibit the LACI activity in human serum. In a reaction mixture containing VIIa, Xa, Ca2+, and purified LACI(HG2), the apparent half-life (t1/2) for TF activity was 20 seconds. The presence of heparin accelerated the initial rate of inhibition threefold. Antithrombin III alpha alone had no effect, but antithrombin III alpha with heparin abrogated the TF inhibition. LACI(HG2) also inhibited Xa with an apparent t1/2 of 50 seconds. Heparin enhanced the rate of Xa inhibition 2.5-fold, whereas phospholipids and Ca2+ slowed the reaction 2.5-fold. Xa inhibition was demonstrable with both chromogenic substrate (S-2222) and bioassays, but no complex between Xa and LACI(HG2) could be visualized by sodium dodecyl sulfate-polyacrylamide gel electrophoresis (SDS-PAGE). Nondenaturing PAGE, however, showed that LACI(HG2) bound to Xa but not to X or Xa inactivated by diisopropyl fluorophosphate. Thus, LACI(HG2) appears to bind to Xa at or near its active site. Bovine factor Xa lacking its gamma-carboxyglutamic acid-containing domain, BXa(-GD), through treatment with alpha-chymotrypsin, was used to further investigate the Xa requirement for VIIa/TF inhibition by LACI(HG2). LACI(HG2) bound to BXa(-GD) and inhibited its catalytic activity against a small molecular substrate (Spectrozyme Xa), though at a rate approximately sevenfold slower than native BXa. Preincubation of LACI(HG2) with saturating concentrations of BXa(-GD) markedly retarded the subsequent inhibition of BXa. The VII(a)/TF complex was not inhibited by LACI(HG2) in the presence of BXa(-GD), and further, preincubation of LACI(HG2) with BXa(-GD) slowed the inhibition of VIIa/TF after the addition of native Xa. The results are consistent with the hypothesis that inhibition of VII(a)/TF involves the formation of a VIIa-TF-XA-LACI complex that requires the GD of XA.(ABSTRACT TRUNCATED AT 400 WORDS)
Similar articles
- The lipoprotein-associated coagulation inhibitor.Broze GJ Jr, Girard TJ, Novotny WF.Broze GJ Jr, et al.Prog Hemost Thromb. 1991;10:243-68.Prog Hemost Thromb. 1991.PMID:2008533Review.
- Endogenous phosphorylation of the lipoprotein-associated coagulation inhibitor at serine-2.Girard TJ, McCourt D, Novotny WF, MacPhail LA, Likert KM, Broze GJ Jr.Girard TJ, et al.Biochem J. 1990 Sep 15;270(3):621-5. doi: 10.1042/bj2700621.Biochem J. 1990.PMID:2122883Free PMC article.
- Inhibition of factor VIIa-tissue factor coagulation activity by a hybrid protein.Girard TJ, MacPhail LA, Likert KM, Novotny WF, Miletich JP, Broze GJ Jr.Girard TJ, et al.Science. 1990 Jun 15;248(4961):1421-4. doi: 10.1126/science.1972598.Science. 1990.PMID:1972598
- Lipoprotein-associated coagulation inhibitor (LACI) is a cofactor for heparin: synergistic anticoagulant action between LACI and sulfated polysaccharides.Wun TC.Wun TC.Blood. 1992 Jan 15;79(2):430-8.Blood. 1992.PMID:1346095
- Tissue factor pathway.McVey JH.McVey JH.Baillieres Clin Haematol. 1994 Sep;7(3):469-84. doi: 10.1016/s0950-3536(05)80094-0.Baillieres Clin Haematol. 1994.PMID:7841596Review.
Cited by
- The C-terminus of tissue factor pathway inhibitor α is required for its interaction with factors V and Va.Ndonwi M, Girard TJ, Broze GJ Jr.Ndonwi M, et al.J Thromb Haemost. 2012 Sep;10(9):1944-6. doi: 10.1111/j.1538-7836.2012.04834.x.J Thromb Haemost. 2012.PMID:22738072Free PMC article.No abstract available.
- Refined regional assignment of the human tissue factor pathway inhibitor (TFPI) gene to chromosome band 2q32 by non-isotopic in situ hybridization.Van der Logt CP, Kluck PM, Wiegant J, Landegent JE, Reitsma PH.Van der Logt CP, et al.Hum Genet. 1992 Jul;89(5):577-8. doi: 10.1007/BF00219189.Hum Genet. 1992.PMID:1353057No abstract available.
- Rationale for a randomized controlled trial comparing two prophylaxis regimens in adults with severe hemophilia A: the Hemophilia Adult Prophylaxis Trial.Ragni MV.Ragni MV.Expert Rev Hematol. 2011 Oct;4(5):495-507. doi: 10.1586/ehm.11.52.Expert Rev Hematol. 2011.PMID:21939418Free PMC article.Clinical Trial.
- Productive recognition of factor IX by factor XIa exosites requires disulfide linkage between heavy and light chains of factor XIa.Marcinkiewicz MM, Sinha D, Walsh PN.Marcinkiewicz MM, et al.J Biol Chem. 2012 Feb 24;287(9):6187-95. doi: 10.1074/jbc.M111.291989. Epub 2011 Dec 29.J Biol Chem. 2012.PMID:22207756Free PMC article.
- Thromboelastography as a better indicator of hypercoagulable state after injury than prothrombin time or activated partial thromboplastin time.Park MS, Martini WZ, Dubick MA, Salinas J, Butenas S, Kheirabadi BS, Pusateri AE, Vos JA, Guymon CH, Wolf SE, Mann KG, Holcomb JB.Park MS, et al.J Trauma. 2009 Aug;67(2):266-75; discussion 275-6. doi: 10.1097/TA.0b013e3181ae6f1c.J Trauma. 2009.PMID:19667878Free PMC article.
Publication types
MeSH terms
Substances
Related information
Grants and funding
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Miscellaneous